EarlyHealth Group
EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm
EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm
DUBAI, United Arab Emirates, Oct. 12, 2025 (GLOBE NEWSWIRE) -- EarlyHealth Group, a global pharmaceutical services and life sciences solutions company, has acquired a 50 % equity stake in CYB3R Limited, one of the Gulf’s fastest-growing cybersecurity firms headquartered in Dubai. This strategic diversification and cross-industry investment positions CYB3R with a global footprint whilst expanding its delivery of turnkey solutions to the life sciences industry and government organizations.
CYB3R, owned by tech entrepreneurs Alex Halsall and Jack Tupper, has rapidly gained prominence by securing critical infrastructure and sensitive data in regulated industries across the Middle East and Europe. By embedding CYB3R’s capabilities into EarlyHealth’s global platform, the partnership will scale operations internationally and deliver turnkey solutions that safeguard clinical studies, institutional programs, and government initiatives.
“With a growing portfolio of 1,200 international enterprises and public organizations, our partnership with EarlyHealth marks the next step in scaling CYB3R’s capabilities globally and delivering tailored cybersecurity solutions to our core sectors,” said Alex Halsall, Chief Executive Officer of CYB3R. “Together, we will establish a new benchmark for trusted, compliance-first digital security.”
CYB3R’s leadership team will remain in place post-acquisition, ensuring continuity in managing the current customer base while expanding its capabilities to serve new global markets.
EarlyHealth’s third acquisition this year underlines its drive to build a global conglomerate at the intersection of healthcare and digital transformation, delivering innovative solutions that expand access for patients, empower industry, and strengthen government capabilities worldwide.
About EarlyHealth Group
EarlyHealth Group is a global pharmaceutical services and life sciences company supporting manufacturing, clinical studies, and market access across 60 countries. The Group partners with biopharma, research institutions, and governments to make healthcare accessible through compliant, end-to-end solutions across the value chain.
About CYB3R
CYB3R is a Dubai-headquartered advanced cybersecurity company providing state-of-the-art SOC operations, managed detection and response (MDR), vulnerability testing, and compliance advisory. With a strong focus on applying AI to enhance security maturity, governance, risk and compliance (GRC), and data protection, CYB3R serves a diverse client base that includes government entities, healthcare providers, financial institutions, education networks, and international service providers.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/26f5855c-3e3a-4fa3-875b-be4bf1bc69ad
For media inquiries, please contact EarlyHealth Group Communications: press@early-health.com

Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SALI7.12.2025 02:14:21 CET | Press release
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
Evaxion6.12.2025 20:00:00 CET | Press release
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Genmab A/S6.12.2025 15:30:00 CET | Press release
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Io Therapeutics, Inc.6.12.2025 14:05:00 CET | Press release
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
Scatec ASA6.12.2025 08:00:00 CET | Press release
Scatec starts commercial operation at Grootfontein solar power plant in South Africa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom